No connection

Search Results

QIPT vs SPRO

QIPT
Quipt Home Medical Corp
BEARISH
Price
$3.65
Market Cap
$162.3M
Sector
Healthcare
AI Confidence
85%
SPRO
Spero Therapeutics, Inc.
BEARISH
Price
$2.75
Market Cap
$159.2M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
QIPT
--
SPRO
18.33
Forward P/E
QIPT
182.5
SPRO
-2.48
P/B Ratio
QIPT
1.59
SPRO
2.63
P/S Ratio
QIPT
0.61
SPRO
2.38
EV/EBITDA
QIPT
6.41
SPRO
17.01

Profitability

Gross Margin
QIPT
72.38%
SPRO
42.42%
Operating Margin
QIPT
1.54%
SPRO
76.05%
Profit Margin
QIPT
-4.03%
SPRO
12.83%
ROE
QIPT
-9.31%
SPRO
16.3%
ROA
QIPT
-0.83%
SPRO
4.99%

Growth

Revenue Growth
QIPT
32.0%
SPRO
174.5%
Earnings Growth
QIPT
--
SPRO
--

Financial Health

Debt/Equity
QIPT
1.02
SPRO
0.05
Current Ratio
QIPT
1.04
SPRO
7.59
Quick Ratio
QIPT
0.6
SPRO
7.4

Dividends

Dividend Yield
QIPT
--
SPRO
--
Payout Ratio
QIPT
0.0%
SPRO
0.0%

AI Verdict

QIPT BEARISH

QIPT exhibits significant financial fragility, highlighted by a weak Piotroski F-Score of 3/9 and a concerning Quick Ratio of 0.60. While revenue growth is robust at 32% YoY, the company struggles with consistent profitability and a track record of missing earnings estimates. The current valuation is disconnected from fundamentals, evidenced by an extreme Forward P/E of 182.50. Despite a recent price rally to 52-week highs, the underlying deterministic health metrics suggest a high risk of regression.

Strengths
Strong Gross Margin of 72.38%
Robust YoY Revenue Growth of 32.00%
Low Price-to-Sales ratio (0.61)
Risks
Weak financial health (Piotroski F-Score 3/9)
Poor liquidity position (Quick Ratio 0.60)
Extreme Forward P/E ratio of 182.50
SPRO BEARISH

SPRO exhibits a critical divergence between its explosive revenue growth and its underlying financial health, evidenced by a weak Piotroski F-Score of 2/9. While the company maintains a strong current ratio (7.59) and low debt, the current price of $2.75 trades at a significant premium to both its Graham Number ($1.88) and Intrinsic Value ($1.05). This valuation gap, combined with aggressive insider selling by the CEO and COO and a bearish technical trend, suggests the recent 1-year price surge is unsustainable. The negative forward P/E further indicates an expectation of returning to losses despite recent revenue spikes.

Strengths
Exceptional YoY revenue growth of 174.50%
Very high liquidity with a current ratio of 7.59
Minimal leverage with a Debt/Equity ratio of 0.05
Risks
Severe financial health deterioration indicated by Piotroski F-Score (2/9)
Strong bearish insider signal with multiple sales by CEO and COO
Significant overvaluation relative to Graham and Intrinsic value baselines

Compare Another Pair

QIPT vs SPRO: Head-to-Head Comparison

This page compares Quipt Home Medical Corp (QIPT) and Spero Therapeutics, Inc. (SPRO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile